Thursday, September 24, 2026
ExploreSearch
Via News
Source trace. Via News points to the documents behind its reporting and shows what we drew from each — so you can check any claim. How we source
Source document· November 20, 2025

Anti-Obesity Drug Market to Reach USD 82.55 Billion in 2032, Exclusive Report by Coherent Market Insights

View original at globenewswire.com
Anti-Obesity Drug Market to Reach USD 82.55 Billion in 2032, Exclusive Report by Coherent Market Insights Burlingame, CA, Nov…
Opening lines of the source · short snapshot — read the full document at the original

What we drew from this source

The claims Via News extracted from this document. We point to the source; we don't replace it.

  • The Global Anti-Obesity Drug Market is estimated to be valued at USD 25.87 Bn in 2025 and is expected to reach USD 82.55 Bn by 2032

    80% confidence

  • High cost of treatment and growing competition from non-pharmacological approaches might slow down market growth to some extent during the forecast period

    80% confidence

  • GLP-1 receptor agonists segment is expected to account for a market share of 22.1% in 2025

    80% confidence

  • GLP-1 receptor agonists like Eli Lilly's Mounjaro and Novo Nordisk's Wegovy are revolutionizing obesity treatment

    80% confidence

  • More than 1 billion people will be living with obesity by 2030

    80% confidence

  • The global anti-obesity drug industry is set to experience strong growth, owing to rising prevalence of obesity, escalating health and wellness awareness, growing popularity of combination therapies, and advancements in new drug formulations

    80% confidence

  • North America is expected to retain its dominance, capturing 38.3% of the global market share in 2025

    80% confidence

  • Asia Pacific, with an estimated share of 24.2% in 2025, is anticipated to emerge as a highly lucrative market for anti-obesity drug companies

    80% confidence

  • The market will exhibit a compound annual growth rate (CAGR) of 18.01% from 2025 to 2032

    80% confidence

  • Prescription drugs segment is slated to dominate the industry, accounting for nearly two-thirds of the global anti-obesity drug market share by 2025

    80% confidence
What we know · the intelligence behind this page
Live from the substrate
What we're seeing
Enterprise AI Agents Go Mainstream, But Trustworthy Data Access Lags Adoption
A wave of enterprise AI agent activity — fresh funding (Latitude's $35M Series A), a run of CB Insights CEO interviews spotlighting fintech- and healthcare-focused agent startups (Covecta, Penguin AI, Maisa AI), and major platform partnerships (Microsoft-Mistral, Manulife-Microsoft AI governance, Siemens-NVIDIA agentic EDA, Box's agent security controls) — signals agentic AI moving from pilot to production across financial and enterprise workflows. Yet Google Cloud's own research shows adoption is outrunning data readiness (companies average AI access to only 45% of their data, with 'data laggards' capped near 30%), while insider selling at incumbent C3.ai hints at mixed investor conviction even as the broader ecosystem accelerates.
Our read on the data ›
Signals we're tracking
Satellite-Terrestrial Network Integration Acceleration
Increased investment and launches in hybrid satellite-cellular networks across telecom industry; competitive responses from other carriers; regulatory activity around satellite spectrum; expansion of emergency/rural connectivity use cases
Patterns we're watching ›
Where sources disagree
ING Group
Both facts record the same metric (shares_outstanding) for ING Group at the identical observation date (2025-12-31). FACT A states 2,902,437,688 shares; FACT B states 2,902 million shares (2,902,000,000). The difference is 437,688 shares (~0.015%). This is a genuine value conflict, though the discrepancy appears to result from FACT B rounding to the nearest million while FACT A provides the precise count.
We flag conflicts openly ›
Recently verified
✓ Checked against the original source
4,983
facts traced to their source — and we flag the ones that don't hold up.
101 entities tracked4,983 facts checked against source5,305 source documents archived
Query this data → isubstrate.com
Anti-Obesity Drug Market to Reach USD 82.55 Billion in 2032, Exclusive Report by Coherent Market Insights — Source | Via News | Via News